CIK 0001682852
- Large accelerated filer
Moderna, Inc.
Sign in to watch- Ticker
- MRNA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813467528
- Phone
- +1 617-714-6500
- Business address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- Moderna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $50,775,837
- in 5 filings, $50.8M under 10b5-1 plans
Net −$50,775,837. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-15 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −7,115 | $129.12 | $919K | 5,426,223 |
| 2023-06-15 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −14,277 | $129.77 | $1.9M | 5,411,946 |
| 2023-06-15 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −40,000 | 107,155 | ||
| 2023-06-15 | Hoge Stephen President | Sale 10b5-1 | −15,000 | $125.93 | $1.9M | 1,617,303 |
| 2023-06-14 | Bancel Stephane Chief Executive Officer | Exercise or conversion 10b5-1 | +40,000 | $0.99 | $40K | 5,451,946 |
| 2023-06-14 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −10,642 | $125.32 | $1.3M | 5,441,304 |
| 2023-06-14 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −20,848 | $126.10 | $2.6M | 5,420,456 |
| 2023-06-14 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −8,510 | $127.25 | $1.1M | 5,411,946 |
| 2023-06-14 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −40,000 | 147,155 | ||
| 2023-06-14 | AFEYAN NOUBAR Director | Sale 10b5-1 | −5,471 | $125.43 | $686K | 2,151,738 |
| 2023-06-14 | AFEYAN NOUBAR Director | Sale 10b5-1 | −5,997 | $126.17 | $757K | 2,145,741 |
| 2023-06-14 | AFEYAN NOUBAR Director | Sale 10b5-1 | −3,002 | $127.19 | $382K | 2,142,739 |
| 2023-06-14 | AFEYAN NOUBAR Director | Sale 10b5-1 | −530 | $128.15 | $68K | 2,142,209 |
| 2023-06-08 | Bancel Stephane Chief Executive Officer | Exercise or conversion 10b5-1 | +40,000 | $0.99 | $40K | 5,451,946 |
| 2023-06-08 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −22,215 | $123.58 | $2.7M | 5,429,731 |
| 2023-06-08 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −17,396 | $124.53 | $2.2M | 5,412,335 |
| 2023-06-08 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −389 | $125.22 | $49K | 5,411,946 |
| 2023-06-08 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −40,000 | 187,155 | ||
| 2023-06-08 | Klinger Shannon Thyme Chief Legal Officer | Sale 10b5-1 | −565 | $124.09 | $70K | 6,516 |
| 2023-06-07 | Bancel Stephane Chief Executive Officer | Exercise or conversion 10b5-1 | +40,000 | $0.99 | $40K | 5,451,946 |
Page 43 of 66 · 1,314 trades